EMERGENT BIOSOLUTIONS INC (EBS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EBS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EBS | Director; Chief Executive Officer | 64 | ["strong background in biomedicines", "corporate finance", "tenure as Chief Executive Officer of Pathalys Pharma, Inc.", "experience gained from senior positions throughout his career"] | ["Audit and Finance", "Scientific Review"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LQDA | Chief Executive Officer and Director | 57 | ["Chief Executive Officer since March 2008","Director of Envisia Therapeutics Inc. from November 2013 until November 2017","Director of Aralez Pharmaceuticals, Inc. from June 2010 until August 2018","President of Centocor, Inc. from June 2006 to March 2008","President of Ortho McNeil Neurologics, Inc. from July 2004 to June 2006","Vice President of central nervous system business of Ortho McNeil Janssen Pharmaceuticals, Inc. from October 2001 to July 2004","Various roles at Eli Lilly and Company from June 1988 to October 2001","Bachelor of Science in Pharmacy from UNC","Master of Business Administration from UNC","Extensive experience in business and healthcare product development"] | [] | 2019 |
Biography sourced from the proxy statement filing.
Mr. Fowler has served as a director since October 2023. Mr. Fowler is the Chief Executive Officer of Pathalys Pharma, Inc., a biomedicines company focused on chronic kidney disease. He previously served as Chief Executive Officer of Liquidia Technologies (Nasdaq), transforming the company from an early-stage research platform into a publicly traded biomedicines company. While at Liquidia, Mr. Fowler also co-founded and served as Chief Executive Officer of Envisia Therapeutics (acquired), an ophthalmology company focused on therapeutics. Prior to Liquidia, Mr. Fowler worked for seven years with Johnson & Johnson, serving as President of Centocor, Inc., a global multi-billion dollar subsidiary focused on biomedicines, and President of Ortho-McNeil Neurologics, a company focused on neurological disorders. Mr. Fowler started his career with Eli Lilly and Company, working for 13 years in a variety of sales, marketing and business development roles in both the pharmaceutical and medical device divisions. Mr. Fowler is the past chair of NCBIO and a past chair of the UNC Eshelman School of Pharmacy Foundation. He is a native of Raleigh, NC and earned his B.S. degree in Pharmacy and M.B.A., both from the University of North Carolina at Chapel Hill. Qualifications: We believe Mr. Fowler s qualifications to serve on our Board of Directors include his strong background in biomedicines, corporate finance and tenure as Chief Executive Officer of Pathalys Pharma, Inc. and experience gained from senior positions he has held throughout his career.